News and Press Releases
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
3 December 2025 -- Amsterdam, The Netherlands and Massachusetts, US -- VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2025
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
3 December 2025 -- Pennsylvania, US -- Annovis Bio, Inc, a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2025
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate
2 December 2025 -- Clermont-Ferrand, France -- Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules 2 December 2025 -- Washington State, US -- As drug developers face increasing pressure to lower...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
1 December 2025 -- Zurich, Switzerland -- Xlife Sciences AG, together with saniva diagnostics GmbH, today announced a landmark achievement: NeuroMex is the world’s first certified and clinically validated medical device for...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: December 1, 2025
VarmX to present at the American Society of Hematology (ASH) Annual Meeting & Exposition
Poster presentation highlights Phase 1 data showing VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects 1 December 2025 -- Leiden, The Netherlands -- VarmX, a...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: December 1, 2025
Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance
IBP-9414 targets mortality and gastrointestinal injury in premature infants With Breakthrough Therapy designation for gastro-intestinal mortality and Rare Paediatric Disease designations, IBP-9414 is on an accelerated path to commercialisation PPQ...
Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: December 1, 2025
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support
Telomir-1 has now entered GMP preparation, and Ketamir-2 has completed the Phase 1 SAD stage, reflecting steady advancement of both programmes These milestones mark tangible progress in development and demonstrate...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 26, 2025
Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting
Parma, Italy – 26 November 2025 – Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announced new data presented at the British Thoracic Society (BTS) Winter...
Category:
Posted: November 26, 2025
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
The Barts Life Sciences Cluster Launches in Whitechapel, East London
With planned investment of over £800m, the Cluster brings together Barts Health NHS Trust and private investors to unite clinical excellence and commercial innovation Science Minister Lord Vallance said: “we...
Category: Other, Pharmaceutical
Posted: November 25, 2025
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly...
Category: Drug Discovery, Other, Pharmaceutical
Posted: November 25, 2025
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Chancellor Friedrich Merz Visits Sonotec – High-Tech Ultrasound Technology “Made in Halle (Saale)” in the Center of His Inaugural Visit
As part of his official inaugural visit to Saxony-Anhalt, German Chancellor Friedrich Merz visited the headquarters of SONOTEC GmbH in Halle (Saale) on Tuesday, November 18, 2025. He was accompanied...
Category:
Posted: November 24, 2025
Clinigen finalises acquisition of SSI Strategy
London, UK – 21 November 2025 – Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, today confirmed the close of its acquisition of SSI Strategy,...
Category:
Posted: November 21, 2025
